Financial StabilityOnce the Udenyca divestment is reflected in Q2, Coherus expects to have ~$250MM in cash on hand, providing about two years of operational runway.
Market OpportunityFor Loqtorzi, the company is focused on expanding penetration in its approved nasopharyngeal carcinoma indication, which represents a $150M-$200M opportunity, as well as label expansion through partnered combinations.
Strategic TransitionCoherus has made significant positive progress as it has completed its transition to a novel oncology company, including what is considered an attractive sale of its biosimilar business, allowing the company to extinguish its debt and provide funding for the next ~18 months as it executes on driving Loqtorzi sales.